INPLASY PROTOCOL

Corresponding author:
Wen Zeng

zengw1010@163.com

Author Affiliation:
National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Bio-targeting Theranostics, Guangxi Medical University, Nanning, Guangxi, China.

Review Stage at time of this submission: Preliminary searches.

Conflicts of interest: None declared.

Adoptive cellular immunotherapy for the treatment of patients with ovarian cancer: A systematic review and meta-analysis

Zeng, W[1]; He, J[2]; Huang, Y[3].

Review question / Objective: To evaluate the therapeutic efficacy of dendritic cells (DC) alone, cytokine-induced killer (CIK) cells alone and the combination of DC and CIK cells in the treatment of ovarian cancer, we performed a systemic review and meta-analysis of the relevant published clinical studies.

Condition being studied: Numerous studies have yielded inconsistent results on the efficacy of DC-CIK cell therapy in the treatment of ovarian cancer. In this study, we performed the first systematic review and meta-analysis of clinical data on DC-CIK cell therapy for ovarian cancer patients in the existing literature, determined the efficiency of DC-CIK cell therapy, and provide guidance for further research and clinical applications.

INPLASY registration number: This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 13 September 2021 and was last updated on 13 September 2021 (registration number INPLASY202190039).

INTRODUCTION

Review question / Objective: To evaluate the therapeutic efficacy of dendritic cells (DC) alone, cytokine-induced killer (CIK) cells alone and the combination of DC and CIK cells in the treatment of ovarian cancer, we performed a systemic review and meta-analysis of the relevant published clinical studies.

Condition being studied: Numerous studies have yielded inconsistent results on the efficacy of DC-CIK cell therapy in the treatment of ovarian cancer. In this study, we performed the first systematic review and meta-analysis of clinical data on DC-CIK cell therapy for ovarian cancer patients in the existing literature, determined the efficiency of DC-CIK cell therapy, and provide guidance for further research and clinical applications.

METHODS

Participant or population: Patients were diagnosed with ovarian cancer based on histopathology.

Intervention: DC-CIK cell therapy.

Comparator: Traditional therapy.

Study designs to be included: Randomized Controlled Trial.

Eligibility criteria: All of the potential publications were independently screened by two reviewers. Duplicates were excluded. Reviews, meta-analyses, conference abstracts, letters, editorials, and protocols were also excluded. Any publications that did not concern DC-CIK cell therapy and ovarian cancer were eliminated. Single-arm trials, non-randomized controlled trials and phase I trials were also excluded.

Information sources: PubMed, EMBASE, and the Cochrane Library.

Main outcome(s): Many trials, including many patients, were included in our systemic review and meta-analysis. The intervention measures are effective or ineffective to the treatment of the subjects.

Quality assessment / Risk of bias analysis: The Cochrane System Evaluation Manual Intervention was used to evaluate the quality of the randomized control clinical trials. Funnel plots were constructed to assess the risk of publication bias.

Strategy of data synthesis: The meta-analysis was performed using RevMan software, version 5.3 (The Cochrane Collaboration, London, UK).

Subgroup analysis: Undetermined.

Sensitivity analysis: We performed sensitivity analyses, defined a priori, to assess the robustness of our conclusions. This was achieved by repeating the analyses to explore the influence of the following factors on effect size.

Country(ies) involved: China.

Keywords: ovarian cancer, dendritic cell, cytokine-induced killer cell, meta-analysis.

Contributions of each author:
Author 1 - Wen Zeng.
Author 2 - Jian He.
Author 3 - Yong Huang.